Intellia Therapeutics
Trade Intellia Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About NTLA
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.
NTLA Key Statistics
NTLA News
Wells Fargo downgraded Intellia Therapeutics (NTLA) to Equal Weight from Overweight with a price target of $17, down from $45. Given the occurrence of the Hy’s...
Intellia Therapeutics Inc ((NTLA)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 5...
William Blair downgraded Intellia Therapeutics (NTLA) to Market Perform from Outperform after the company announced that it has voluntarily paused enrollment an...
Analyst ratings
73%
of 26 ratingsMore NTLA News
(RTTNews) - Intellia Therapeutics, Inc. (NTLA) fell 43.79% to $14.39, down $11.21, after providing an update on its Magnitude Phase 1/2 clinical trials evaluati...
Guggenheim analyst Debjit Chattopadhyay downgraded Intellia Therapeutics (NTLA) to Neutral from Buy. Published first on TheFly – the ultimate source for real-t...
Intellia tanks as it pauses late-stage CRISPR gene-editing trials after one patient was hospitalized Intellia dropped sharply on Monday after it announced that...
In a report released today, Mitchell Kapoor from H.C. Wainwright maintained a Buy rating on Intellia Therapeutics, with a price target of $25.00. Elevate Your I...
BofA lowered the firm’s price target on Intellia Therapeutics (NTLA) to $30 from $36 and keeps a Buy rating on the shares after the company paused dosing and sc...
Intellia Therapeutics Inc. (NASDAQ:NTLA) shares tumbled after the company said it had temporarily paused patient dosing and screening in its Phase 3 MAGNITUDE a...
Intellia Therapeutics (NTLA) stock plummeted on Monday after the biotechnology company announced an update from its MAGNITUDE and MAGNITUDE-2 Phase 3 clinical t...